

7. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. *Am J Gastroenterol*. 2001; 96(4): 990–996.
8. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. *Gastroenterology*. 2000; 118(3): 487–496.
9. Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and metaanalysis. *Clin Gastroenterol Hepatol*. 2013; 11(6): 620–629.
10. Ganz RA, Peters JH, Horgan S, Bemelman WA, Dunst CM, Edmundowicz SA, Lipham JC, Luketich JD, Melvin WS, Oelschlager BK, Schlack-Haerer SC, Smith CD, Smith CC, Dunn D, Taiganides PA. Esophageal sphincter device for gastroesophageal reflux disease. *N Engl J Med*. 2013; 368(8): 719–727.
11. Zadeh J, Andreoni A, Treitl D, Ben-David I. Spotlight on the Linx™ Reflux Management System for the treatment of gastroesophageal reflux disease: evidence and research. *Med Devices (Auckl)*. 2018; 11: 291–300.
12. Inoue H, Ito H, Ikeda H, Sato C, Sato H, Phalanusitthepha C1, Hayee B2, Eleftheriadis N1, Kudo SE3. Anti-reflux mucosectomy for gastroesophageal reflux disease in the absence of hiatus hernia: a pilot study. *Ann Gastroenterol*. 2014; 27(4): 346–351.
13. Inoue H, Sumi K, Tatsuta T, Ikebuchi Y, Tuason J. Clinical Results of Antireflux Mucosectomy (ARMS) for Refractory Gerd. *Gastrointestinal Endoscopy*, 2017; 85(5): AB120.
14. Chan DS, Campbell F, Edwards P, Jasani B, Williams GT, Lewis WG. Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer. *ISRN Surg*. 2012; 2012: 804891.
15. Van Cutsem E, Kang Y, Chung H, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). *Journal of Clinical Oncology* 27, no. 15_suppl.
16. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol*. 2014; 15(11): 1224–1235.
17. Ruhstaller T, et al. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). *Ann Oncol*. 2018; 29(6): 1386–1393.
18. Zhang Y, Pan T, Zhong X, Cheng C. Resistance to cetuximab in EGFR-overexpressing esophageal squamous cell carcinoma xenografts due to FGFR2 amplification and overexpression. *J Pharmacol Sci*. 2014; 126(1): 77–83.
19. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. *Nature*. 2011; 480(7378): 480–489.
20. Razack AH. Bacillus Calmette–Guerin and bladder cancer. *Asian J Surg*. 2007; 30(4): 302–309.
21. Bartnik A, Nirmal AJ, Yang S. Peptide Vaccine Therapy in Colorectal Cancer. *Vaccines (Basel)*. 2013; 1(1): 1–16. Published online 2012 Aug 23.
22. Kono K, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. *Journal of Translational Medicine* 2012; 10: 14.
23. Bujas T, Marusic Z, Peric Balja M, Mijic A, Kruslin B, Tomas D. MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma. *Eur J Histochem*. 2011; 55(1): e7.
24. Kageyama S. Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. *Clin Cancer Res*. 2015; 21(10): 2268–2277.
25. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nature Reviews. Cancer*. March 2012; 12(4): 252–264.
26. Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H, Saraf S, Koshiji M. Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475). *Journal of Clinical Oncology* 34, no. 4_suppl (February 1 2016) 7–7.
27. Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA, Yamaguchi K, Balogh A, Sanchez T, Moehler M. Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. *Clin Cancer Res*. 2017; 23(19): 5671–5678.
28. Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. *J Clin Oncol*. 2018; 36(28): 2836–2844.
29. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and Individualized Drug Therapy. *Annual Review of Medicine*, 2006; 57(1): 119–137.
30. Yao Y, He Y, Han X, Ji C, Hu B. Clinical research of individualized therapy in advanced esophageal cancer based on the ERCC1 C8092A genotype. *Oncology Letters*. 2018.
31. Künzli HT, van Berge Henegouwen MI, Gisbertz SS, van Esser S, et al. Pilot-study on the feasibility of sentinel node navigation surgery in combination with thoracoscopic lymphadenectomy without esophagectomy in early esophageal adenocarcinoma patients. *Dis Esophagus*. 2017; 30(11): 1–8.